Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

NCT03792841 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

212

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Metastatic Castration-resistant Prostate Cancer
Prostate Cancer

Interventions

DRUG: acapatamab
DRUG: Pembrolizumab
DRUG: Etanercept
DRUG: Cytochrome P450 (CYP) Cocktail

Sponsor

Amgen